Get the Stockscreener App
5.32
1.92%
+0.10
Why is Editas Medicine Inc (EDIT) Stock down?
We've noticed a 5.62% decline in Editas Medicine Inc (EDIT) stock during the 2024-04-12 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
17 Oct, 2023:
Editas Medicine Inc. (EDIT) dropped by 6.20% from $7.26 to $6.81 in the trading on Tuesday October 17, 2023. The reason why EDIT stock down today is due to stock downgrade by analyst. Cantor Fitzgerald has downgraded Editas (EDIT) stock to Neutral from Overweight. The analyst assumes that Editas' sickle cell therapy EDIT-301 surpassing exa-cel and lovo-cel in HbF production could pose a formidable challenge. The analysts Eric Schmidt and Rick Bienkowsk also note that EDIT-301's ability to demonstrate clinical differentiation to these candidates is unclear.
1.53%
3.38%
Cap:
|
Volume (24h):